Cancer stem cell-mediated therapeutic resistance in hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is a highly heterogeneous malignancy. In the clinic, therapeutic resistance is largely attributed to tumor heterogeneity. Growing evidence indicates that cancer stem cells (CSCs) are the major source of tumor heterogeneity. Hence, uncovering the resistance mechanisms associated with CSC properties is essential for developing effective therapeutics. CSCs resemble embryonic stem cells. Embryonic development-related genes and signaling pathways are usually abnormally active and function as oncofetal drivers in HCC. Multiple strategies have been applied to identify oncofetal drivers. The mechanisms of CSC resistance could also provide reliable biomarkers to predict treatment failure. Precisely targeting these specific CSC properties may be effective in preventing or annihilating therapy resistance. This review provides an overview of drug resistance mechanisms associated with CSC traits and summarize therapeutic strategies against drug resistance.

Keywords

Hepatocellular carcinoma / heterogeneity / cancer stem cell / drug resistance / precision therapy

References

[1] Chen S,Wen W.Targeted therapy for hepatocellular carcinoma: challenges and opportunities.Cancer Lett2019;460:1-9

[2] Greten TF,Li G.Targeted and immune-based therapies for hepatocellular carcinoma.Gastroenterology2019;156:510-24 PMCID:PMC6340758

[3] Huang A,Chung WY,Zhou J.Targeted therapy for hepatocellular carcinoma.Signal Transduct Target Ther2020;5:146 PMCID:PMC7419547

[4] Sangro B,Hervás-Stubbs S.Advances in immunotherapy for hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2021;18:525-43 PMCID:PMC8042636

[5] Hadjimichael C,Papadopoulou N,Papamatheakis J.Common stemness regulators of embryonic and cancer stem cells.World J Stem Cells2015;7:1150-84 PMCID:PMC4620423

[6] Garcia-Mayea Y,Masson F,LLeonart ME.Insights into new mechanisms and models of cancer stem cell multidrug resistance.Semin Cancer Biol2020;60:166-80

[7] Huang T,Xu D.Stem cell programs in cancer initiation, progression, and therapy resistance.Theranostics2020;10:8721-43 PMCID:PMC7392012

[8] Zhou HM,Zhang X.Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents.Signal Transduct Target Ther2021;6:62 PMCID:PMC7884707

[9] Lee TK,Ma S.Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.Nat Rev Gastroenterol Hepatol2022;19:26-44

[10] Prasetyanti PR.Intra-tumor heterogeneity from a cancer stem cell perspective.Mol Cancer2017;16:41 PMCID:PMC5314464

[11] Zheng H,Hernandez MO.Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma.Hepatology2018;68:127-40 PMCID:PMC6033650

[12] Wang XQ,Lui EL.Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma.Int J Cancer2012;131:E163-72

[13] Li MM,Guan XY,Liu M.Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits.Exp Hematol Oncol2021;10:53 PMCID:PMC8590337

[14] Silva-Diz V, Lorenzo-Sanz L, Bernat-Peguera A, Lopez-Cerda M, Muñoz P. Cancer cell plasticity: Impact on tumor progression and therapy response.Semin Cancer Biol2018;53:48-58

[15] Polyak K.Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.Nat Rev Cancer2009;9:265-73

[16] Mani SA,Liao MJ.The epithelial-mesenchymal transition generates cells with properties of stem cells.Cell2008;133:704-15 PMCID:PMC2728032

[17] Huang Z,Liu AY.Differentiation and transdifferentiation potentials of cancer stem cells.Oncotarget2015;6:39550-63 PMCID:PMC4741845

[18] Gupta PB,Skibinski A,Kuperwasser C.Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance.Cell Stem Cell2019;24:65-78 PMCID:PMC7297507

[19] Liu M,Sun Y.A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets.Proc Natl Acad Sci U S A2020;117:6103-13 PMCID:PMC7084088

[20] Liu M,Ma NF.CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors.Hepatology2016;63:1544-59

[21] Kong FE,Tang YQ.Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate.Sci Transl Med2021;13:eabb6282

[22] Yang XD,Qi L.PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma.Mol Cancer2021;20:20 PMCID:PMC7824946

[23] Cheng W,Xi SY.Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma.Nat Commun2021;12:7142 PMCID:PMC8654996

[24] Paul R,Fan Y.Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications.Pharmacol Ther2022;231:107985 PMCID:PMC8844041

[25] Boix L,Rhodes AC.Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF-β pathway.Oncotarget2016;7:71309-29 PMCID:PMC5342080

[26] Fabregat I.Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis.Front Oncol2018;8:357 PMCID:PMC6139328

[27] Xia Y,Li H.MIRLET7BHG promotes hepatocellular carcinoma progression by activating hepatic stellate cells through exosomal SMO to trigger hedgehog pathway.Cell Death Dis2021;12:326 PMCID:PMC7997896

[28] Bayik D.Cancer stem cell-immune cell crosstalk in tumour progression.Nat Rev Cancer2021;21:526-36 PMCID:PMC8740903

[29] Shi GM,Fan J.Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials.J Cancer Res Clin Oncol2008;134:1155-63

[30] Hu C,Li J.Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling.Carcinogenesis2008;29:2289-97

[31] Bhagyaraj E,Kumar S.TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR.Cell Cycle2019;18:3589-602 PMCID:PMC6927732

[32] Fung SW,Yip CW.The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma.Cancer Lett2019;457:98-109

[33] Wang M,Zhi X.SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.Biomed Pharmacother2020;129:110315

[34] Wei L,Lv L.The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma.Mol Cancer2019;18:147 PMCID:PMC6814027

[35] Wilhelm SM,Newell P,Llovet JM.Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther2008;7:3129-40

[36] Hu B,Li YC.CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-κB oncogenic signaling.Clin Transl Med2020;10:e233 PMCID:PMC7708822

[37] Lu S,Xu G.CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.Cell Death Dis2018;9:646 PMCID:PMC5974417

[38] Toh TB,Hooi L,Chow EK.Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.J Hepatol2020;72:104-18

[39] Cao W,Liu J.LGR5 marks targetable tumor-initiating cells in mouse liver cancer.Nat Commun2020;11:1961 PMCID:PMC7181628

[40] Gao Y,Fu J.Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.J Hepatol2022;76:148-59

[41] Wu CX,Chok SH.Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.Theranostics2018;8:3737-50 PMCID:PMC6071527

[42] Wang S,Xun X.Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.J Exp Clin Cancer Res2020;39:22 PMCID:PMC6986013

[43] Leung HW,Leung CON.NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.Cancer Lett2020;476:48-56

[44] Leung HW,Lau EY.EPHB2 activates β-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma.Cancer Res2021;81:3229-40

[45] Pollutri D,Marinelli S.The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.Cell Death Dis2018;9:4 PMCID:PMC5849044

[46] Xu J,Tang M.N⁶-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling.Mol Cancer2020;19:163 PMCID:PMC7681956

[47] Li W,He C.LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.J Exp Clin Cancer Res2019;38:183 PMCID:PMC6499991

[48] Song W,Liu M.TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p.Mol Ther2021;29:2601-16 PMCID:PMC8353204

[49] Zhou K,Qiao L.Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC.Mol Cancer2022;21:6 PMCID:PMC8722008

[50] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[51] Ma XL,Tang WG.CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma.J Hematol Oncol2020;13:11 PMCID:PMC7003355

[52] Ma XL,Hu B.CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.J Hematol Oncol2019;12:37 PMCID:PMC6458749

[53] Talukdar S,Das SK.EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells.Adv Cancer Res2020;147:161-88

[54] Jin H,Lv Y.EGFR activation limits the response of liver cancer to lenvatinib.Nature2021;595:730-4

[55] He X,Suzuki Y.EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.Sci Rep2022;12:8007 PMCID:PMC9107466

[56] Lu Y,Huang W.Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance.Cell Death Discov2021;7:359 PMCID:PMC8602346

[57] Hou W,Malnassy G.Integrin subunit beta 8 contributes to lenvatinib resistance in HCC.Hepatol Commun2022;6:1786-802 PMCID:PMC9234648

[58] Wang J,Zheng L.FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells.Theranostics2021;11:5045-60 PMCID:PMC7978301

[59] Myojin Y,Maesaka K.ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.Clin Cancer Res2021;27:1150-61

[60] Arechederra M,Abdouni A.ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.J Hepatol2021;74:893-906

[61] Han T,Zhang J.Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis.Cell Death Dis2022;13:200 PMCID:PMC8891362

[62] Zhang P,Wen P,Cui Y.circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma.Mol Ther Nucleic Acids2022;27:293-303 PMCID:PMC8718824

[63] Grothey A,Pavlakis N,Bruix J.Evolving role of regorafenib for the treatment of advanced cancers.Cancer Treat Rev2020;86:101993

[64] Liu R,Tian L.Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.Cancer Lett2019;443:34-46

[65] Wang J,Han Q.Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.Cancer Lett2019;444:82-93 PMCID:PMC6492280

[66] Suemura S,Myojin Y.CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma.Cancers (Basel)2019;11:1362 PMCID:PMC6770429

[67] Huang H,Liu K.RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.J Gastroenterol Hepatol2021;36:3429-37

[68] Karabicici M,Ozhan G,Firtina Karagonlar Z.Changes in Wnt and TGF-β signaling mediate the development of Regorafenib resistance in hepatocellular carcinoma cell line HuH7.Front Cell Dev Biol2021;9:639779 PMCID:PMC8386122

[69] Dai Z,Peng R,Han Q.Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.Cancer Lett2022;524:161-71

[70] Dai X,Hu Y.Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.Theranostics2021;11:3489-501 PMCID:PMC7847682

[71] Pinyol R,Llovet JM.Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC.Clin Cancer Res2019;25:2021-3 PMCID:PMC6445700

[72] Ruiz de Galarreta M,Molina-Sánchez P.β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma.Cancer Discov2019;9:1124-41 PMCID:PMC6677618

[73] Zhu GQ,Wang B.Targeting HNRNPM inhibits cancer stemness and enhances antitumor immunity in wnt-activated hepatocellular carcinoma.Cell Mol Gastr Hep2022;13:1413-47 PMCID:PMC8938476

[74] Wei CY,Zhang PF,Wan JK.PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.J Hepatol2022;77:163-176

[75] Huang XY,Wei CY.Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis.Mol Cancer2020;19:92 PMCID:PMC7236145

[76] Kilgour E,Brady G.Liquid biopsy-based biomarkers of treatment response and resistance.Cancer Cell2020;37:485-95

[77] Parikh AR,Elagina L.Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.Nat Med2019;25:1415-21 PMCID:PMC6741444

[78] Ho DW,Sze KM.Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer.Cancer Lett2019;459:176-85

[79] Zhou L,Wong TL.Lineage tracing and single-cell analysis reveal proliferative Prom1+ tumour-propagating cells and their dynamic cellular transition during liver cancer progression.Gut2022;71:1656-68

[80] Ma S,Zheng BJ,Guan XY.CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.Oncogene2008;27:1749-58

[81] Caruso S,Pilet J.Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.Gastroenterology2019;157:760-76

[82] Wei L,Law CT.Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.Nat Commun2019;10:4681 PMCID:PMC6794322

[83] Samanta D,Andrabi SA,Gilkes DM.PHGDH expression is required for mitochondrial Redox homeostasis, breast cancer stem cell maintenance, and lung metastasis.Cancer Res2016;76:4430-42

[84] He S,Li C.PDXliver: a database of liver cancer patient derived xenograft mouse models.BMC Cancer2018;18:550 PMCID:PMC5944069

[85] Broutier L,Verstegen MM.Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.Nat Med2017;23:1424-35 PMCID:PMC5722201

[86] Nuciforo S,Matter MS.Organoid models of human liver cancers derived from tumor needle biopsies.Cell Rep2018;24:1363-76 PMCID:PMC6088153

[87] Cho K,Seo SH.Genetically engineered mouse models for liver cancer.Cancers (Basel)2019;12:14 PMCID:PMC7016809

[88] Wang N,Li MY.Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies.Ther Adv Med Oncol2018;10:1758835918816287 PMCID:PMC6304707

[89] Liu YC,Lin KH.Cancer stem cell functions in hepatocellular carcinoma and comprehensive therapeutic strategies.Cells2020;9:1331 PMCID:PMC7349579

[90] Danan G.RUCAM in drug and herb induced liver injury: the update.Int J Mol Sci2015;17:14 PMCID:PMC4730261

[91] Galle PR,Qin S.Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.Lancet Oncol2021;22:991-1001

[92] Cheng AL,Ikeda M.Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J Hepatol2022;76:862-73

[93] immunotherapy makes strides against HCC.Cancer Discov2022;12:OF1

[94] Akce M,Bekaii-Saab TS.Frontline therapy for advanced hepatocellular carcinoma: an update.Therap Adv Gastroenterol2022;15:17562848221086126 PMCID:PMC9006370

[95] Highlights of prescribing information for nexavar (sorafenib) tablets, for oral use. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf [Last accessed on 22 Sep 2022]

[96] NEXAVAR. Available from: https://www.rxlist.com/nexavar-drug.htm#indications [Last accessed on 22 Sep 2022]

[97] Highlights of prescribing information for lenvima® (lenvatinib) capsules, for oral use. Available from: https://www.lenvima.com/-/media/Project/EISAI/Lenvima/PDF/prescribing-information.pdf [Last accessed on 22 Sep 2022]

[98] LENVIMA. Available from: https://www.rxlist.com/lenvima-drug.htm#description [Last accessed on 22 Sep 2022]

[99] Systemic anti cancer therapy protocol. Protocol ref: MPHAABHCGA (Version No: 1.0). 95. Available from: https://www.clatterbridgecc.nhs.uk/application/files/6016/1650/0037/Atezolizumab_Bevacizumab_Hepatocellular_Carcinoma_Protocol_V1.0.pdf [Last accessed on 22 Sep 2022]

[100] NSW government. eviQ. Available from: https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/hepatic/3881-hcc-advanced-or-metastatic-atezolizumab-and-b#side-effects [Last accessed on 22 Sep 2022]

[101] STIVARGA. Available from: https://www.rxlist.com/stivarga-drug.htm#description [Last accessed on 22 Sep 2022]

[102] CABOMETYX. Available from: https://www.rxlist.com/cabometyx-drug.htm#interaction [Last accessed on 22 Sep 2022]

[103] CYRAMZA. Available from: https://www.rxlist.com/cyramza-drug.htm#dosage [Last accessed on 22 Sep 2022]

[104] Highlights of prescribing information for KEYTRUDA® (pembrolizumab). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdf [Last accessed on 22 Sep 2022]

[105] PEMBROLIZUMAB. Available from: https://www.rxlist.com/consumer_pembrolizumab_keytruda/drugs-condition.htm#what_other_drugs_interact_with_pembrolizumab [Last accessed on 22 Sep 2022]

[106] Nivolumab. Available from: https://www.pediatriconcall.com/drugs/nivolumab/29 [Last accessed on 22 Sep 2022]

[107] Ipilimumab. Available from: https://www.pediatriconcall.com/drugs/ipilimumab/167 [Last accessed on 22 Sep 2022]

[108] Fairfax BP,Roberts IS.Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.BMC Cancer2012;12:590 PMCID:PMC3575366

[109] Shikdar S,Choi E.A rare case of sorafenib induced liver injury in a patient with recurrent Hurthle cell carcinoma.J Case Rep Images Oncol2018;4:100051Z10SS2018

[110] Douros A,Andersohn F.Drug-induced liver injury: results from the hospital-based berlin case-control surveillance study.Br J Clin Pharmacol2015;79:988-99 PMCID:PMC4456131

[111] Brooks AJ,Chapman BA.Two cases of severe liver injury possibly related to 5-fluorouracil and calcium folinate.Intern Med J2007;37:344-5

[112] Kreitman K,Kothadia JP.Successful treatment of crizotinib-induced fulminant liver failure: a case report and review of literature.Case Reports Hepatol2020;2020:8247960 PMCID:PMC7085870

[113] Cardenas V,Mody R,Fontana RJ.Incidence and sequelae of liver injury among children treated for solid tumors: analysis of a large single-center prospective cohort.J Pediatr Gastroenterol Nutr2020;71:197-202

[114] Tzadok R,Aouizerate J.Acute liver failure following a single dose of atezolizumab, as assessed for causality using the updated RUCAM.Case Rep Gastrointest Med2022;2022:5090200 PMCID:PMC8967548

[115] Ahmed T,Shah B.Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy.BMJ Case Rep2015;2015:bcr2014208102 PMCID:PMC4513455

[116] Al-Nattah S,Caldis M,Nicholas Rose W.Plasmapheresis for pembrolizumab-induced hepatitis in a patient with squamous cell carcinoma and prior orthotopic liver transplantation.Case Reports Hepatol2022;2022:5908411 PMCID:PMC8799356

[117] Weber S,Rotter I.Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis.Liver Int2019;39:1906-17

[118] Li X,Li X,Yang W.Application of artificial liver in immune-related liver injury induced by immune checkpoint inhibitor: case reports and review of the literature.Front Immunol2022;13:1001823 PMCID:PMC9478575